B-Raf and the inhibitors: from bench to bedside

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

2012 • 2,861 citations

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 • 2,120 citations

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

2012 • 2,111 citations

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

2010 • 1,729 citations

High frequency of BRAF mutations in nevi

2002 • 1,701 citations

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

2010 • 1,438 citations

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

2011 • 1,378 citations

BRAF mutation predicts sensitivity to MEK inhibition

2005 • 1,312 citations

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

2010 • 1,218 citations

BrafV600E cooperates with Pten loss to induce metastatic melanoma

2009 • 1,119 citations

BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas

2003 • 1,042 citations

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

2012 • 997 citations

BRAFMutations in Hairy-Cell Leukemia

2011 • 975 citations

BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications

2007 • 960 citations

BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

2005 • 956 citations

BRAF Mutation in Papillary Thyroid Carcinoma

2003 • 915 citations

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

2012 • 915 citations

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

2012 • 885 citations

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

2006 • 636 citations

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

2011 • 632 citations

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

2009 • 546 citations

The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer

2007 • 463 citations

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

2010 • 444 citations

Targeted Expression of BRAFV600E in Thyroid Cells of Transgenic Mice Results in Papillary Thyroid Cancers that Undergo Dedifferentiation

2005 • 415 citations

BRAF mutations are associated with some histological types of papillary thyroid carcinoma

2004 • 366 citations

BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing

2004 • 344 citations

RAF protein-serine/threonine kinases: Structure and regulation

2010 • 332 citations

BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.

2003 • 301 citations

MEK and the inhibitors: from bench to bedside

2013 • 259 citations

Mutant BRAF Melanomas—Dependence and Resistance

2011 • 245 citations

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

2010 • 233 citations

Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutation

2011 • 219 citations

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

2011 • 211 citations

BRAF mutations in metastatic melanoma: a possible association with clinical outcome.

2003 • 208 citations

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

2010 • 169 citations

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression

2009 • 168 citations

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

2011 • 167 citations

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application

2013 • 163 citations

Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy

2007 • 159 citations

B-raf, a new member of the raf family, is activated by DNA rearrangement.

1988 • 149 citations

The Primary Occurrence ofBRAF^V600EIs a Rare Clonal Event in Papillary Thyroid Carcinoma

2011 • 137 citations

High Prevalence and Possible de Novo Formation of BRAF Mutation in Metastasized Papillary Thyroid Cancer in Lymph Nodes

2005 • 126 citations

A High Percentage of BRAFV600E Alleles in Papillary Thyroid Carcinoma Predicts a Poorer Outcome

2012 • 118 citations

Primary Structure of v- raf : Relatedness to the src Family of Oncogenes

1984 • 112 citations

Back to the roots: the remarkable RAF oncogene story

2006 • 111 citations

Role of BRAF in Thyroid Oncogenesis

2011 • 110 citations

Targeting insulin-like growth factor axis in hepatocellular carcinoma

2011 • 108 citations

Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF

2011 • 101 citations

Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse

2011 • 98 citations

A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors

2009 • 96 citations

Clinical Implication of Highly Sensitive Detection of the BRAF V600E Mutation in Fine-Needle Aspirations of Thyroid Nodules: A Comparative Analysis of Three Molecular Assays in 4585 Consecutive Cases in a BRAF V600E Mutation-Prevalent Area

2012 • 96 citations

Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan

2010 • 92 citations

Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer

2011 • 86 citations

Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR

2013 • 75 citations

Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells

2012 • 73 citations

Diagnostic value of pyrosequencing for the BRAF^V600E mutation in ultrasound‐guided fine‐needle aspiration biopsy samples of thyroid incidentalomas

2008 • 72 citations

Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma

2011 • 71 citations

A Rapid and Simple Detection Method for theBRAF^T1796AMutation in Fine-Needle Aspirated Thyroid Carcinoma Cells

2004 • 66 citations

Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials

2013 • 62 citations

Allele Specific Locked Nucleic Acid Quantitative PCR (ASLNAqPCR): An Accurate and Cost-Effective Assay to Diagnose and Quantify KRAS and BRAF Mutation

2012 • 61 citations

Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor

2012 • 49 citations

KRAS mutation testing in clinical practice

2014 • 45 citations

Current management and novel agents for malignant melanoma

2012 • 45 citations

Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.

2011 • 45 citations

Detection ofBRAFMutations in Thyroid Nodules by Allele-Specific PCR Using a Dual Priming Oligonucleotide System

2010 • 41 citations

BRAFmutation testing in clinical practice

2012 • 37 citations

Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene.

1992 • 37 citations

A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma

2012 • 34 citations

JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines

2012 • 24 citations

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma

2012 • 22 citations

CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer

2012 • 22 citations

Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP

2004 • 12 citations

Colorimetric approach to high-throughput mutation analysis

2005 • 9 citations

Abstract 2517: Pharmacodynamic biomarkers for ARQ 736, a small molecule BRAF inhibitor

2010 • 6 citations